Liraglutide Injection

(Ship Cold)

Available Dosage Strengths

6 mg/mL

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Liraglutide, a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an incretin mimetic. Incretins are released from the gastrointestinal tract into the systemic circulation to improve glycemic control. The drug is used for the following indications:

For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.
For the reduction of cardiovascular mortality, non-fatal myocardial infarction, or non-fatal stroke in persons with type 2 diabetes mellitus and established cardiovascular disease.
For the treatment of obesity and for chronic weight management as an adjunct to reduced-calorie diet and lifestyle modifications. [1,2,3]

Mechanism of Action

Liraglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. Liraglutide specifically has 97% amino acid sequence homology to endogenous GLP-1. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation. [1,2,3]

Adverse Reactions

Common

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia.
Headache, dizziness, and injection site reactions. [1,2,3]

Contraindications & Precautions

Contraindications:

Hypersensitivity to liraglutide or its components.
In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2.
In patients who are pregnant.

Precautions:

In patients with a history of pancreatitis and gall bladder disease.
In patients with renal and hepatic impairment. [1,2,3]

Storage

Unopened pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). In-use pens: May be kept at room temperature (15°C to 30°C or 59°F to 86°F) for up to 30 days. Do not freeze. [1,2]

References

Liraglutide (Victoza) Prescribing Information – Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf. Revised August 2017. Accessed May 26, 2025.
FDA. Drug Approval Package: Saxenda (liraglutide). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf. Revised April 2023. Accessed May 26, 2025.
Clinical Pharmacology liraglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/

Disclaimer

This sheet is a summary. It may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.